Want to join the conversation?
$AGN, which competes with $MYL and $AMGN, said that for 2016, it expects to launch a multi-dose preservative free formulation of RESTASIS, a new botox indication; ACZONE 7.5%; XEN Stent for glaucoma; Oculeve for dry eye. The company has more than 70 projects in mid-to-late stage development and has multiple programs in each therapeutic areas.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.